Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) saw strong trading volume on Thursday. Approximately 351,116 shares traded hands during trading, an increase of 140% from the average daily volume of 146,077 shares. The stock last traded at $16.54 and had previously closed at $16.48.
Analyst Ratings Changes
Separately, Zacks Research cut shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Astellas Pharma has an average rating of “Moderate Buy”.
Get Our Latest Report on Astellas Pharma
Astellas Pharma Price Performance
The firm has a 50-day simple moving average of $15.19 and a 200-day simple moving average of $14.80. The firm has a market capitalization of $29.90 billion, a PE ratio of 12.11 and a beta of 0.06. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.20 and a quick ratio of 0.93.
Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.41 by ($0.06). The business had revenue of $3.98 billion for the quarter, compared to analysts’ expectations of $3.79 billion. Astellas Pharma had a net margin of 16.18% and a return on equity of 26.13%. As a group, equities analysts forecast that Astellas Pharma Inc. will post 1.40 earnings per share for the current year.
About Astellas Pharma
Astellas Pharma Inc. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company was formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, and is headquartered in Tokyo. Astellas develops treatments across areas including oncology, urology, immunology and women’s health. Its medicines include Xtandi (enzalutamide), used to treat certain forms of prostate cancer, and Prograf (tacrolimus), an immunosuppressant used in organ transplantation.
Read More
- Five stocks we like better than Astellas Pharma
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
- Midterm Fallout, NVIDIA Turmoil, Anthropic’s IPO: Is Broadcom a Steal?
- 3 Pharmaceutical Stocks That Offer Safety and Growth
- If Japan’s Stock Market Rally Returns, These 3 ETFs Could Benefit
Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
